Formulation and characterization of mometasone furoate and formoterol fumarate containing dry powder inhaler by spray drying and homogenization methods

被引:2
|
作者
Akdag, Yagmur [1 ]
Gulsun, Tugba [1 ]
Izat, Nihan [1 ]
Oner, Levent [1 ]
Sahin, Selma [1 ]
机构
[1] Hacettepe Univ, Fac Pharm, Dept Pharmaceut Technol, Ankara, Turkey
来源
JOURNAL OF RESEARCH IN PHARMACY | 2022年 / 26卷 / 02期
关键词
Mometasone furoate monohydrate; formoterol fumarate dihydrate; dry powder inhaler; asthma; combined drug therapy; BACTERIAL-CONTAMINATION; LUNG-CANCER; HPLC METHOD; INHALATION; PARTICLES; STABILITY; DEVICES; ASTHMA;
D O I
10.12991/
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This study aimed to design and characterize an inhalable dry powder of mometasone furoate monohydrate (MFM) combined with the formoterol fumarate dihydrate (FFD). Homogenization in water and spray drying processes were used to prepare the dry powders for inhalation. The physicochemical characteristics of the dry powders were evaluated by differential scanning calorimetry (DSC), Fourier transform infrared spectroscopy (FT-IR), X-ray diffractometry (XRD) and scanning electron microscopy (SEM). The particle size distribution, content uniformity, solid behavior and aerodynamic properties of DPI were also determined. After the micronization process, the particle sizes of the raw materials significantly decreased. SEM images implied that FFD covered the MFM surface during the spray drying step, and uniform particles were produced. X-ray and DSC results demonstrated that MFM did not show any change in crystal structure after homogenization and spray drying processes. DSC analysis of DPI formulation exhibited that the same melting point of MFM was observed when the drugs were spray dried. FT-IR spectra exhibited the characteristic peaks for MFM in DPI formulation. Content uniformity results showed that the developed production method is suitable for manufacturing uniform formulations. According to angle of repose, Hausner ratio and Carr's index results, DPI formulation has preferable flow properties. In addition, emitted dose, mass median aerodynamic diameter, fine particle fraction showed that the DPI formulation could ensure drug delivery to the alveoli. This study showed that the combination of homogenization and spray drying methods is suitable to obtain a DPI formulation containing MFM and FFD with a particle size less than 5 mu m to reach alveoli.
引用
收藏
页码:383 / 396
页数:14
相关论文
共 50 条
  • [1] Comparison of the systemic bioavailability of mometasone furoate after oral inhalation from a mometasone furoate/formoterol fumarate metered-dose inhaler versus a mometasone furoate dry-powder inhaler in patients with chronic obstructive pulmonary disease
    Kosoglou, Teddy
    Hubbell, James
    Xuan, Fengjuan
    Cutler, David L.
    Meehan, Alan G.
    Kantesaria, Bhavna
    Wittmer, Bret A.
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2013, 8 : 107 - 116
  • [2] Mometasone furoate dry powder inhaler for the treatment of asthma
    Fausnight, Tracy B.
    Craig, Timothy J.
    EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (17) : 2707 - 2712
  • [3] Drug delivery performance of the mometasone furoate dry powder inhaler
    Yang, TT
    Li, S
    Wyka, B
    Kenyon, D
    JOURNAL OF AEROSOL MEDICINE-DEPOSITION CLEARANCE AND EFFECTS IN THE LUNG, 2001, 14 (04): : 487 - 494
  • [4] Development of a pharmaceutically robust formoterol fumarate formulation for use in a multidose dry powder inhaler
    Armanni, A
    Brambilla, G
    Musa, R
    Taverna, MC
    Gill, R
    Meakin, BJ
    Western, K
    JOURNAL OF AEROSOL MEDICINE-DEPOSITION CLEARANCE AND EFFECTS IN THE LUNG, 2004, 17 (01): : 93 - 105
  • [5] Investigation of Appropriate Inhalation Technique for Mometasone Furoate Dry Powder Inhaler
    Yokoyama, Haruko
    Ito, Kanako
    Mihashi, Hirokazu
    Shiraishi, Yasuyuki
    Takayanagi, Risa
    Yamada, Yasuhiko
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2016, 39 (10) : 1576 - 1580
  • [6] Mometasone furoate dry-powder inhaler for the control of persistent asthma
    D'Urzo, Anthony
    EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (16) : 2871 - 2884
  • [7] Effects of a novel roflumilast and formoterol fumarate dry powder inhaler formulation in experimental allergic asthma
    Suzuki, Erika Yoko
    Simon, Alice
    da Silva, Adriana Lopes
    Amaro, Maria Ines
    de Almeida, Gabriella Silva
    Agra, Lais Costa
    Cabral, Lucio Mendes
    Macedo Rocco, Patricia Rieken
    Healy, Anne Marie
    de Sousa, Valeria Pereira
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2020, 588
  • [8] Comparative efficacy and safety of mometasone furoate dry powder inhaler and budesonide Turbuhaler®
    Carlsson, LG
    Edsbäcker, S
    EUROPEAN RESPIRATORY JOURNAL, 2001, 17 (06) : 1332 - 1333
  • [9] Effects of treatment with mometasone furoate dry powder inhaler in children with persistent asthma
    Berger, William E.
    Milgrom, Henry
    Chervinsky, Paul
    Noonan, Michael
    Weinstein, Steven F.
    Lutsky, Barry N.
    Staudinger, Heribert
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2006, 97 (05) : 672 - 680
  • [10] Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler®
    Bousquet, J
    D'Urzo, A
    Hebert, J
    Barraza, CH
    Boulet, LP
    Suárez-Chacón, R
    Harnest, U
    Lundbäck, B
    Morales, GM
    Nieminen, MM
    Nolop, KB
    Visser, S
    Lutsky, BN
    EUROPEAN RESPIRATORY JOURNAL, 2000, 16 (05) : 808 - 816